| Q39388122 | 'Get in Early'; Biofilm and Wax Moth (Galleria mellonella) Models Reveal New Insights into the Therapeutic Potential of Clostridium difficile Bacteriophages |
| Q63230054 | 2019 update of the WSES guidelines for management of () infection in surgical patients |
| Q40462283 | A Comprehensive Study of Costs Associated With Recurrent Clostridium difficile Infection. |
| Q42872710 | An outbreak case of Clostridium difficile-associated diarrhea among elderly inpatients of an intensive care unit of a tertiary hospital in Rio de Janeiro, Brazil |
| Q35208564 | Clostridium difficile Infection and Inflammatory Bowel Disease: A Review. |
| Q30235905 | Clostridium difficile infection in inflammatory bowel disease: challenges in diagnosis and treatment |
| Q37814046 | Clostridium difficile infection: epidemiology, risk factors and management |
| Q39413120 | Clostridium difficile testing in the clinical laboratory by use of multiple testing algorithms |
| Q34213711 | Clostridium difficileinfection and inflammatory bowel disease: Understanding the evolving relationship |
| Q42613450 | Comparison of a commercial multiplex real-time PCR to the cell cytotoxicity neutralization assay for diagnosis of clostridium difficile infections. |
| Q36280168 | Cost-effectiveness in Clostridium difficile treatment decision-making |
| Q37782566 | Does the handling time of unrefrigerated human fecal specimens impact the detection of Clostridium difficile toxins in a hospital setting? |
| Q37858531 | Emerging therapies for Clostridium difficile infections |
| Q51624311 | Epidemiological Patterns and Hospital Characteristics Associated with Increased Incidence ofClostridium difficileInfection in Quebec, Canada, 1998–2006 |
| Q35140090 | Evaluation of a loop-mediated isothermal amplification assay for diagnosis of Clostridium difficile infections |
| Q40813899 | Fecal Transplantation for Clostridium Difficile-"All Stool May Not Be Created Equal". |
| Q36379088 | Fecal microbiota transplantation in relapsing Clostridium difficile infection |
| Q37125998 | Genetic risk factors for Clostridium difficile infection in ulcerative colitis |
| Q41911754 | Genotoxicity revaluation of three commercial nitroheterocyclic drugs: nifurtimox, benznidazole, and metronidazole |
| Q37798821 | Impact ofClostridium difficileon inflammatory bowel disease |
| Q41395591 | Low awareness but positive attitudes toward fecal transplantation in Ontario physicians |
| Q37403990 | Mortality, Hospital Costs, Payments, and Readmissions Associated With Clostridium difficile Infection Among Medicare Beneficiaries |
| Q33704701 | Multilocus sequence typing of Clostridium difficile |
| Q55405974 | Novel Antimicrobials for the Treatment of Clostridium difficile Infection. |
| Q38611301 | Prediction of Recurrent Clostridium Difficile Infection Using Comprehensive Electronic Medical Records in an Integrated Healthcare Delivery System |
| Q37026857 | Predictors of severe outcomes associated with Clostridium difficile infection in patients with inflammatory bowel disease |
| Q27021390 | Risk factors for recurrence, complications and mortality in Clostridium difficile infection: a systematic review |
| Q37825531 | Systematic review: Clostridium difficile and inflammatory bowel disease. |
| Q84998007 | Temporal trends in disease outcomes related to Clostridium difficile infection in patients with inflammatory bowel disease |
| Q28750385 | The changing epidemiology of Clostridium difficile infections |
| Q38757930 | Therapies on the horizon for Clostridium difficile infections |
| Q24634294 | Treating Clostridium difficile infection with fecal microbiota transplantation |
| Q39638001 | Type IV pili promote early biofilm formation by Clostridium difficile |
| Q34643177 | Vitamin D deficiency is associated with community-acquired clostridium difficile infection: a case-control study |
| Q26795429 | WSES guidelines for management of Clostridium difficile infection in surgical patients |